Clinical Trial Update: Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy

View source ↗

Summary

This update reports long-term outcomes from a first-line regimen of nivolumab plus ipilimumab with two cycles of chemotherapy for metastatic non-small cell lung…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Chemotherapy (chemotherapy)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Metastatic Non-small Cell Lung Cancer | Status: ACTIVE_NOT_RECRUITING